Menu Search
Equities

ANI Pharmaceuticals Inc

ANIP:NMQ

ANI Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)55.86
  • Today's Change0.76 / 1.38%
  • Shares traded309.00
  • 1 Year change+7.82%
  • Beta0.7347
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ANI Pharmaceuticals Inc grew revenues 53.87% from 316.39m to 486.82m while net income improved from a loss of 47.90m to a gain of 18.78m.
Gross margin59.79%
Net profit margin-1.28%
Operating margin0.76%
Return on assets-0.65%
Return on equity-2.10%
Return on investment-0.77%
More ▼

Cash flow in USDView more

In 2023, ANI Pharmaceuticals Inc increased its cash reserves by 315.38%, or 167.89m. The company earned 118.96m from its operations for a Cash Flow Margin of 24.44%. In addition the company generated 67.44m cash from financing while 18.51m was spent on investing.
Cash flow per share2.66
Price/Cash flow per share22.76
Book value per share20.44
Tangible book value per share-9.46
More ▼

Balance sheet in USDView more

ANI Pharmaceuticals Inc has a Debt to Total Capital ratio of 59.21%, a lower figure than the previous year's 62.68%.
Current ratio2.74
Quick ratio1.97
Total debt/total equity1.45
Total debt/total capital0.5921
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 127.96%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)-8.16
EPS (TTM) vs
TTM 1 year ago		-189.81
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.